| scholarly article | Q13442814 |
| P2093 | author name string | Kelly W Davis | |
| Rachel E Hanners | |||
| Sean M Lockwood | |||
| Rebekah A Wahking | |||
| Randal L Steele | |||
| P2860 | cites work | Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach | Q24673561 |
| Strategies for discontinuation of proton pump inhibitors: a systematic review | Q27022227 | ||
| ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998 | Q28145422 | ||
| Guidelines for prevention of NSAID-related ulcer complications | Q33412100 | ||
| Antidepressants in functional dyspepsia | Q33805609 | ||
| Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy. | Q34286825 | ||
| Decreased acid suppression therapy overuse after education and medication reconciliation | Q34317683 | ||
| Marked increase in gastric acid secretory capacity after omeprazole treatment | Q34410460 | ||
| Review article: the clinical pharmacology of proton pump inhibitors | Q34526068 | ||
| Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs | Q34552195 | ||
| The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association | Q34552620 | ||
| Long-term proton pump inhibitor therapy and risk of hip fracture | Q34595049 | ||
| Defining Appropriate Use of Proton-Pump Inhibitors Among Medical Inpatients | Q36717591 | ||
| Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. | Q37830663 | ||
| Management of patients with ulcer bleeding | Q37981830 | ||
| Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. | Q38470026 | ||
| Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study | Q38879069 | ||
| Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn: A Randomized Placebo-Controlled Trial | Q39178268 | ||
| Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding | Q39378104 | ||
| Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. | Q39681631 | ||
| ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus | Q40365358 | ||
| Impact of a pharmacist-driven protocol to decrease proton pump inhibitor use in non-intensive care hospitalized adults | Q40569140 | ||
| Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study | Q40783849 | ||
| Reduction of inappropriate exit prescriptions for proton pump inhibitors: A before-after study using education paired with a web-based quality-improvement tool | Q41362180 | ||
| Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression | Q42371575 | ||
| Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse | Q42955085 | ||
| Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial | Q43120420 | ||
| Step-down management of gastroesophageal reflux disease | Q43777297 | ||
| Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs | Q44590209 | ||
| Tobacco smoking cessation and improved gastroesophageal reflux: a prospective population-based cohort study: the HUNT study | Q44799310 | ||
| Risk of death associated with use of PPIs in three cohorts of institutionalized older people in Finland | Q45256718 | ||
| Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy | Q46053053 | ||
| Implementation of a proton pump inhibitor stewardship program | Q47862254 | ||
| Glad you brought it up: a patient-centred programme to reduce proton-pump inhibitor prescribing in general medical practice. | Q51189173 | ||
| Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. | Q51252408 | ||
| The effects of guideline implementation for proton pump inhibitor prescription on two pulmonary medicine wards | Q57259918 | ||
| Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals | Q86270728 | ||
| ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and | Q95416005 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 59-67 | |
| P577 | publication date | 2017-12-13 | |
| P1433 | published in | Hospital pharmacy | Q27711105 |
| P1476 | title | Outcomes From a Pharmacist - led Proton Pump Inhibitor Stewardship Program at a Single Institution | |
| P478 | volume | 53 |
| Q92855804 | Evaluation of a Pharmacist-Driven Protocol to Reduce Inappropriate Use of Acid-Suppressive Medications In the Non-ICU Setting |
| Q92989580 | Guideline implementation is effective at reducing proton pump inhibitor use in hematology-oncology units: A multidisciplinary intervention for reducing Clostridioides difficile risk |
Search more.